Phathom Pharmaceuticals (PHAT) Equity Average (2022 - 2025)
Historic Equity Average for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$414.2 million.
- Phathom Pharmaceuticals' Equity Average fell 9678.96% to -$414.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.2 million, marking a year-over-year decrease of 9678.96%. This contributed to the annual value of -$163.2 million for FY2024, which is 12113.73% down from last year.
- Phathom Pharmaceuticals' Equity Average amounted to -$414.2 million in Q3 2025, which was down 9678.96% from -$372.1 million recorded in Q2 2025.
- In the past 5 years, Phathom Pharmaceuticals' Equity Average ranged from a high of $15.5 million in Q2 2022 and a low of -$414.2 million during Q3 2025
- Over the past 4 years, Phathom Pharmaceuticals' median Equity Average value was -$96.6 million (recorded in 2023), while the average stood at -$145.1 million.
- Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 9948.24% in 2023, then tumbled by 24321849.71% in 2024.
- Quarter analysis of 4 years shows Phathom Pharmaceuticals' Equity Average stood at -$50.6 million in 2022, then increased by 10.57% to -$45.3 million in 2023, then plummeted by 386.78% to -$220.3 million in 2024, then plummeted by 87.97% to -$414.2 million in 2025.
- Its Equity Average was -$414.2 million in Q3 2025, compared to -$372.1 million in Q2 2025 and -$296.0 million in Q1 2025.